Logo Image
|Videos|September 16, 2016

Future Applications of Morphokinetic Cellular Analysis

Andrew Chasteen from Accelerate Diagnostics, Inc, explains future applications of Morphokinetic Cellular Analysis (MCA).

Andrew Chasteen from Accelerate Diagnostics, Inc, explains future applications of Morphokinetic Cellular Analysis (MCA).

Interview Transcript (slightly modified for readability)

“There are future applications where MCA can be helpful. In one case, it may provide information around the concentration of a drug that would kill a cell. Again, today the microbiology lab really can provide minimum inhibitory concentration, which is concentration of a drug or antibiotic that stops it from growing, but doesn’t actually kill it, per se.

Knowing the concentration that would kill the organism is helpful to pharmacists in order to know what dose is effective, as well as to clinicians to know that they are actually eradicating [an] infection versus just slowing it down and hoping that the body’s immune system will take it from there.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more